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Liver transplant recipients have an increased risk for car-
diovascular disease because of a high incidence of obesity,
arterial hypertension, diabetes mellitus, and hyperlipid-
emia. Hyperhomocysteinemia has been found to be an
important risk factor for cardiovascular disease in large
studies. Fasting serum levels of homocysteine were mea-
sured in 105 liver transplant recipients, and hyperhomo-
cysteinemia was defined as a fasting serum homocysteine
level greater than 13 mmol/L. Patients with versus without
hyperhomocysteinemia were compared. The possible as-
sociation of hyperhomocysteinemia with age, sex, cause of
liver disease, time elapsed since liver transplantation, im-
munosuppressive therapy, folic acid level, liver function
test results, renal function, and other cardiovascular risk
factors was investigated. Patients with serum homocys-
teine levels greater than 15 mmol/L were treated with folic
acid, 10 mg/d, and serum homocysteine levels were mea-
sured again 1 to 3 months later in 10 patients. Hyperho-
mocysteinemia was detected in 28 patients (27%). In uni-
variate analysis, it was associated with hepatitis C virus
infection, treatment with mycophenolate mofetil, and
greater serum levels of alkaline phosphatase, g-glutamyl
transpeptidase, urea, and creatinine. In multivariate anal-
ysis, only greater serum levels of creatinine (P 5 .006)
were associated with hyperhomocysteinemia. Treatment
with folic acid resulted in a decrease in fasting serum
homocysteine levels in 9 of the 10 patients tested (P 5
.01). Hyperhomocystinemia, associated with renal dys-
function, is a frequent finding in liver transplant recipi-
ents. Treatment with folic acid may reduce fasting homo-
cysteine levels. (Liver Transpl 2000;6:614-618.)
Cardiovascular disease is a major cause of morbidityand mortality in long-term survivors after liver
transplantation. It is the most frequent nonimmune,
non–immunosuppression-related cause of death in
such patients.1 Cardiac and neurological complications
are more frequent in patients aged older than 60 years,2
a subgroup of transplant recipients that is increasing
during the last years. Some cardiovascular risk factors,
such as obesity, arterial hypertension, hypercholesterol-
emia, and diabetes mellitus, are frequent after liver
transplantation,3 thus increasing their cardiovascular
risk.
Homocysteine is a sulfur-containing amino acid
formed in the metabolism of methionine. In 1969,
McCully4 found extensive arterial thrombosis and ath-
erosclerosis in 2 children with high plasma homocys-
teine concentrations and homocystinuria. Since then,
there has been a growing evidence of the association of
high plasma levels of homocysteine and cardiovascular
disease.5 In the mechanism of this vascular damage, the
rapid auto-oxidation of homocysteine in plasma,
producing such potent reactive oxygen species as super-
oxide and hydrogen peroxide, may be involved.6 Ho-
mocysteine is metabolized by methylation and transsul-
furation. In the first pathway, the methyl donor is N5-
methyltetrahydrofolate. For this reason, folic acid
dietary supplements have been shown to reduce fasting
homocysteine levels.7
On these basis, we studied the incidence of hyper-
homocysteinemia in liver transplant recipients, factors
possibly associated with hyperhomocysteinemia, and its
response to treatment with folic acid.
Patients and Methods
One hundred five adult liver transplant recipients were pro-
spectively studied at different times posttransplantation. After
overnight fasting (.10 hours), a complete blood count and
serum levels of alanine transferase, aspartate aminotransferase,
alkaline phosphatase, g-glutamyl transpeptidase, total biliru-
bin, urea, creatinine, cholesterol, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, triglycerides,
homocysteine, and folic acid were measured. Serum homo-
cysteine levels were determined using a fluorescent polarized
immunoassay run on an IMX system (IMX Homocisteina;
Axis Biochemicals ASA, Oslo, Norway). Serum concentra-
tions of folic acid were measured by chemiluminescent en-
zyme immunoassay (Immulite Folic Acid; Diagnostic Prod-
ucts Corp, Los Angeles, CA). Hyperhomocysteinemia was
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defined as a fasting homocysteine level greater than 13
mmol/L, according to Jacques et al.7
The incidence of other cardiovascular risk factors was re-
corded. Hypercholesterolemia was defined as a fasting serum
cholesterol level greater than 220 mg/dL or the need for
pharmacological therapy to maintain a lower level. Diabetes
mellitus was defined as the need for pharmacological therapy
to maintain normal glucose levels before and after meals.
Arterial hypertension was defined as systolic blood pressure
greater than 140 mm Hg, diastolic blood pressure of 90 mm
Hg or greater, or the need for antihypertensive drugs to main-
tain blood pressure within normal limits. Obesity was defined
as body mass index greater than 30 kg/m2.
Other clinical data were recorded from the patients’ med-
ical histories, including age, sex, cause of liver disease, time
elapsed since liver transplantation, and immunosuppressive
therapy.
The possible association between hyperhomocysteinemia,
the listed laboratory and clinical variables, and the incidence
of other cardiovascular risk factors was investigated using
Mann-Whiney U test for continuous variables and Chi-
Table 1. General Characteristics of the Patients
Age (yr) 58.34 6 0.89
Sex (male/female) 73/32
Cause
Alcoholic cirrhosis 42 (40)
Hepatitis C cirrhosis 30 (29)
Other* 33 (31)
Hepatocellular carcinoma 29 (28)
Current immunosuppressive
therapy
Cyclosporine-based 71; monotherapy 43 (61)
Tacrolimus-based 29; monotherapy 16 (55)
Mycophenolate mofetil–
based 5; monotherapy 5 (100)
Time after liver transplanta-
tion (mo) 45 6 3 (1-144)
,1 yr 22 (21)
1-3 yr 25 (24)
.3 yr 58 (55)
Cardiovascular risk factors
Arterial hypertension 79 (75)
Hypercholesterolemia 40 (38)
Obesity 35 (33)
Diabetes mellitus 12 (11)
NOTE. Values expressed as mean 6 SEM (range) or number
(percent).
*Other includes: primary biliary cirrhosis (8 patients), hemo-
chromatosis (6 patients), hepatitis B cirrhosis (5 patients),
cryptogenic cirrhosis (4 patients), Wilson’s disease (3 pa-
tients), Budd-Chiari syndrome (2 patients), alpha1-antitryp-
sin deficiency (1 patient), autoimmune hepatitis (1 patient),
idiopathic adulthood ductopenia (1 patient), liver metastasis
(1 patient), and polycystic liver disease (1 patient).
Table 2. Clinical Predictive Factors for








(n 5 77) P
Age (yr) 58 6 2 59 6 1 .99
Sex
Men 20 (71) 53 (69) 1.00
Women 8 (29) 24 (31)
Cause
Alcoholic 8 (29) 34 (44) .06
Hepatitis C 13 (46) 17 (22)
Others 7 (25) 26 (34)
Hepatitis C
Yes 13 (46) 17 (22) .03
No 15 (54) 60 (78)
HCC
Yes 6 (21) 23 (30) .47
No 22 (79) 54 (70)
Cyclosporine
Yes 19 (68) 52 (68) 1.00
No 9 (32) 25 (32)
Tacrolimus
Yes 6 (21) 23 (30) .47
No 22 (79) 54 (70)
MMF
Yes 9 (32) 6 (8) .003
No 19 (68) 71 (72)
Azathioprine
Yes 5 (18) 18 (23) .61
No 23 (82) 59 (77)
Prednisone
Yes 7 (25) 13 (17) .40
No 21 (75) 64 (83)
Follow-up (mo) 52 6 7 44 6 3 .34
Hypertension
Yes 24 (86) 55 (71) .20
No 4 (14) 22 (29)
Obesity
Yes 9 (32) 26 (34) 1.00
No 19 (68) 51 (66)
Hypercholesterolemia
Yes 12 (43) 28 (36) .65
No 16 (57) 49 (64)
Diabetes
Yes 5 (18) 7 (9) .30
No 23 (82) 70 (91)
NOTE. Values expressed as number (percent) unless other-
wise noted.
Abbreviations: HCC, hepatocellular carcinoma; MMF, my-
cophenolate mofetil.
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square and Fisher’s exact tests, as appropriate, for categorical
variables. Those variables showing P less than .05 in univari-
ate analysis were entered into logistic regression analysis to
obtain relative risks with 95% confidence intervals adjusted
for confounding factors. Correlations between serum homo-
cysteine levels and continuous variables significantly associ-
ated with hyperhomocysteinemia were assessed by means of
Spearman’s rank-order test. All statistical work was performed
using SPSS for Windows, version 8.0.0 (SPSS Inc, Chicago,
IL).
Patients with fasting homocysteine levels greater than 15
mmol/L were treated with oral folic acid at a dosage of 10
mg/d. Fasting homocysteine levels were determined again 1 to
3 months later in 10 of these patients, and its evolution was
studied using Wilcoxon signed-rank test. In a control group
of 10 patients, homocysteine levels were determined again 3
months after their basal determination without changing
pharmacological treatment or adding vitamin supplements.
Significance was recorded for P of .05 or less. Continuous
variables are expressed as mean 6 SEM.
Results
General characteristics of the patients are listed in Table
1. Induction immunosuppressive therapy combined a
calcineurin inhibitor (either cyclosporine or tacroli-
mus), azathioprine, and prednisone. Long-term mono-
therapy with a calcineurin inhibitor was intended and
was achieved in most patients between posttransplanta-
tion months 6 and 12. Patients with impaired renal
function were treated with mycophenolate mofetil and
partial or complete withdrawal of calcineurin inhibi-
tors.
The mean serum concentration of homocysteine
was 11.0 6 0.4 mmol/L (range, 2.9 to 22.5 mmol/L).
Hyperhomocysteinemia was found in 28 patients
(27%). The study of predictive factors for hyperhomo-
cysteinemia is listed in Tables 2 and 3. Patients with
hyperhomocysteinemia had greater serum levels of al-





(n 5 77) P
AST (IU/L) 27 6 3 23 6 2 .35
ALT (IU/L) 33 6 4 32 6 4 .17
AP (IU/L) 212 6 24 164 6 7 .04
GGT (IU/L) 90 6 37 35 6 5 .007
Total bilirubin (mg/dL) 1.24 6 0.16 1.15 6 0.08 .78
Hemoglobin (g/dL) 12.8 6 0.3 13.2 6 0.2 .34
White blood cell count (103/mL) 4.9 6 0.3 5.1 6 1.9 .60
Platelet count (103/mL) 132 6 9.9 142 6 5.1 .19
Cholesterol (mg/dL) 203 6 9 194 6 4 .22
HDL (mg/dL) 43 6 3 45 6 2 .40
LDL (mg/dL) 135 6 7 126 6 4 .24
Triglycerides (mg/dL) 135 6 14 118 6 7 .26
Urea (g/L) 0.64 6 0.04 0.50 6 0.02 .001
Creatinine (mg/dL) 1.47 6 0.08 1.15 6 0.03 ,.001
Folic acid (ng/mL) 8.4 6 0.8 8.8 6 0.5 .60
Abbreviations: AP, alkaline phosphatase; GGT, g-glutamyl transpeptidase; HDL, high-density lipoprotein cholesterol; LDL, low-
density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 4. Predictive Factors for Hyperhomocysteinemia
After Liver Transplantation by Multivariate Analysis
Relative Risk
(95% confidence interval) P
Creatinine (mg/dL) 41.81 (2.87-609.0) .006
Urea (g/L) 1.98 (0.06-65.44) .70
Alkaline phosphatase
(IU/L) 1.00 (0.99-1.01) .43
GGTP (IU/L) 1.00 (1.0-1.01) .40
Treatment with MMF 2.49 (0.62-9.96) .20
Hepatitis C virus infection 2.65 (0.89-8.20) .09
Abbreviations: GGTP, g-glutamyl transpeptidase; MMF,
mycophenolate mofetil.
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kaline phosphatase, g-glutamyl transpeptidase, urea,
and creatinine, and more frequently underwent trans-
plantation for hepatitis C virus–related liver disease and
were under treatment with mycophenolate mofetil. On
multivariate analysis, the only factor associated with
hyperhomocysteinemia was serum creatinine level (Ta-
ble 4). There was a significant correlation between se-
rum creatinine and homocysteine levels (Fig. 1). Only 8
of 60 patients (13%) with normal serum creatinine
levels (,1.21 mg/dL) had hyperhomocysteinemia
compared with 20 of 45 patients (44%) with high se-
rum creatinine levels (P 5 .001). Patients with high
serum creatinine levels had a relative risk for hyperho-
mocysteinemia of 5.20 (95% confidence interval, 2.01
to 13.43) compared with patients with normal renal
function.
The incidence of other metabolic cardiovascular risk
factors is listed in Table 1. Only 13 patients (12%) had
none of the mentioned cardiovascular risk factors (arte-
rial hypertension, obesity, hypercholesterolemia, diabe-
tes mellitus, and hyperhomocysteinemia), 29 patients
(28%) had 1 risk factor, 33 patients (31%) had 2 risk
factors, 24 patients (23%) had 3 risk factors, and 6
patients (6%) had 4 risk factors. No patient had 5 risk
factors. There was no association between hyperhomo-
cysteinemia and other cardiovascular risk factors.
Treatment with folic acid in patients with fasting
serum homocysteine levels greater than 15 mmol/L was
followed by a reduction in homocysteine levels in 9 of
10 patients (P 5 .01). These results are shown in Figure
2. Mean fasting serum homocysteine levels in these 10
patients were 17.8 6 0.7 mmol/L (range, 15.5 to 22.5
mmol/L) before treatment with folic acid and 13.0 6
1.5 mmol/L (range, 5.9 to 21.4 mmol/L) after treat-
ment. In the control (untreated) group, serum homo-
cysteine levels did not change significantly (11.0 6 0.9
v 12.0 6 0.9 mmol/L).
Discussion
Hyperhomocysteinemia has been found to be an inde-
pendent risk factor for cardiovascular disease.8 Epide-
miological studies have found that patients with hyper-
homocysteinemia have a greater risk for coronary heart
disease, cerebrovascular disease, and peripheral vascular
disease.9 In a large European series, patients with fasting
homocysteine levels greater than 12 mmol/L had twice
the risk for coronary heart disease as patients with lower
levels, whereas the relative risk for coronary heart dis-
ease of a patient with a fasting cholesterol level of 275
mg/dL compared with a patient with 189 mg/dL was
1.4.10 Fortunately, hyperhomocysteinemia may be cor-
rected with folic acid supplements.7 Whether folic acid
supplements reduce the risk for cardiovascular disease is
currently unknown, but it may be presumed because a
greater intake of folate is associated with a lower inci-
dence of cardiovascular disease.11
The results obtained in this study showing that more
than 25% of liver transplant recipients have elevated
fasting homocysteine levels add more evidence of the
increased risk for cardiovascular events in these pa-
tients. In our series, hyperhomocysteinemia was more
prevalent than diabetes mellitus and nearly as prevalent
as hypercholesterolemia and obesity. Hyperhomocys-
teinemia powerfully increases the cardiovascular risk
associated with other risk factors, such as arterial hyper-
tension,10 a very frequent secondary effect of immuno-
suppressive therapy.
Figure 2. Evolution of fasting serum homocysteine levels
after treatment with oral folic acid supplements (10 mg/d)
in 10 patients with fasting serum homocysteine levels
greater than 15 mmol/L.
Figure 1. Correlation between serum creatinine levels
and fasting serum homocysteine levels.
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In our series, the only factor predisposing to hyper-
homocysteinemia was impairment of renal function.
The association of hyperhomocysteinemia and chronic
renal failure has been previously reported,12 but it is
unknown whether it is caused by impaired metabolism
or reduced excretion. Hyperhomocysteinemia has been
proposed as a partial explanation of the accelerated ath-
erosclerosis of patients with end-stage renal disease.6
The existence of hyperhomocysteinemia for a long time
in patients with chronic renal failure may help explain
why cardiovascular disease is the second leading cause
of death in kidney transplant recipients13 as opposed to
liver transplant recipients, who do not have such a high
rate of cardiovascular mortality. Furthermore, end-
stage liver disease is associated with low peripheral vas-
cular resistance and hypocoagulability, probably pro-
tecting patients with cirrhosis from atherosclerosis. In
our study, the association between treatment with my-
cophenolate mofetil and hyperhomocysteinemia found
in univariate analysis may be related to the use of this
drug in patients with impaired renal function to allow
cyclosporine reduction.
The reduction of homocysteine levels after treat-
ment with folic acid shown in previous series and this
report may reduce the cardiovascular risk of patients
with hyperhomocysteinemia. Whether this interven-
tion reduces the incidence of cardiovascular disease and
cardiovascular mortality has to be answered by random-
ized, placebo-controlled trials that are currently under
way. In conclusion, hyperhomocysteinemia is a cardio-
vascular risk factor frequently found in liver transplant
recipients, usually in association with renal dysfunc-
tion. Its association with other posttransplantation car-
diovascular risk factors may be an important cause of
morbidity and mortality in long-term survivors.
References
1. Asfar S, Metrakos P, Fryer J, Verran V, Ghent C, Grant D, et al.
An analysis of late deaths after liver transplantation. Transplan-
tation 1996;61:1377-1381.
2. Zetterman RK, Belle SH, Hoofnagle JH, Lawlor S, Wei Y,
Everhart, J, et al. Age and liver transplantation: A report of the Liver
Transplantation Database. Transplantation 1998;66:500-506.
3. Muñoz SJ. Hyperlipidemia and other coronary risk factors after
orthotopic liver transplantation: Pathogenesis, diagnosis and
management. Liver Transpl Surg 1995;1:29-38.
4. McCully KS. Vascular pathology of homocysteinemia: Implica-
tions for the pathogenesis of arteriosclerosis. Am J Pathol 1969;
56:111-128.
5. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine
and cardiovascular disease. Annu Rev Med 1998;49:31-62.
6. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N
Engl J Med 1998;338:1042-1050.
7. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH.
The effect of folic acid fortification on plasma folate and total
homocysteine concentrations. N Engl J Med 1999;340:1449-
1454.
8. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler
B, Graham I. Hyperhomocysteinemia: An independent risk fac-
tor for vascular disease. N Engl J Med 1991;324:1149-1155.
9. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A
quantitative assessment of plasma homocysteine as a risk factor
for vascular disease. Probable benefits of increasing folic acid
intakes. JAMA 1995;274:1049-1057.
10. Graham MI, Daly LE, Refsum HM, Robinson K, Brattstro¨m
LE, Ueland PM, et al. Plasma homocysteine as a risk factor for
vascular disease. The European Concerted Action Project.
JAMA 1997;277:1775-1781.
11. Rimm EB, Willet WC, Hu FB, Sampson L, Colditz GA, Man-
son JE, et al. Folate and vitamin B6 from diet and supplements
in relation to risk of coronary heart disease among women.
JAMA 1998;279:359-364.
12. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage
renal disease (ESRD): Prevalence, etiology and potential relation-
ship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.
13. Schweitzer EJ, Matas AJ, Gillingham KJ, et al. Causes of renal
allograft loss: Progress in 1980s, challenges for 1990s. Ann Surg
1991;214:679-688.
618 Herrero et al
